Securities Class Action Filed Against Aerie Pharmaceuticals, Inc.

Violations of federal securities laws as a result of a series of materially false statements. The Complaint alleges that, during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose adverse information regarding the Company’s prospects for its lead product candidate, RhopressaTM (“Rhopressa”). On April 23, 2015, the Company issued a press release announcing the results of its first Phase 3 registration trial for Rhopressa. According to the release, “[t]he trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily RhopressaTM compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma.” On this news, shares of Aerie fell $22.52 per share, to close at $12.87 per share on April 24, 2015. Filed in D.N.J.

Lead Plaintiff Deadline: The deadline to file for lead plaintiff in this action is 6/29/2015.

Join This Action: To apply to join this action and be represented by Shepherd, Finkelman, Miller & Shah, LLP, please click here for a certification form to submit your information.

Send Us Information: If you have information about this action that you would like to provide us, please click here.

A Message to Our Clients About Coronavirus COVID-19:

A Message to Our Clients About Coronavirus COVID-19

At Shepherd, Finkelman, Miller & Shah, LLP, we view the safety and well-being of our clients, staff and business partners as our highest priority.

The situation regarding the COVID-19 virus is continually changing, and we are following all recommended guidelines to stay healthy. As a result, our lawyers and staff are working remotely in accordance with the CDC's recommendations. We continue to work for all of our clients and are happy to arrange for phone or video consultations. We are also able to exchange documents via secure drives or email.

Please contact us online or call 866-540-5505 with any questions.

Thank you and take care.